Candel Therapeutics, Inc. CADL
We take great care to ensure that the data presented and summarized in this overview for Candel Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CADL
View all-
Northpond Ventures, LLC1.94MShares$14 Million8.58% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA812KShares$5.86 Million0.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA541KShares$3.91 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$1.05 Million0.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX82.6KShares$596,3350.0% of portfolio
-
Baystate Wealth Management LLC76.9KShares$555,2900.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny56.9KShares$410,8540.0% of portfolio
-
Black Rock Inc. New York, NY47.6KShares$343,5270.0% of portfolio
-
Mariner, LLC Overland Park, KS33.5KShares$241,7250.0% of portfolio
-
Resources Investment Advisors, Llc. Overland Park, KS29.8KShares$215,0330.0% of portfolio
Latest Institutional Activity in CADL
Top Purchases
Top Sells
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Insider Transactions at CADL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 28
2023
|
Jason Amello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,153
-9.07%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
Francesca Barone Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,748
-9.57%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
William Garrett Nichols Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,175
-8.27%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
Paul Peter Tak Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,443
-10.42%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
Seshu Tyagarajan Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,328
-9.05%
|
$0
$0.9 P/Share
|
|
Nov 26
2023
|
Jason Amello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,717
+36.14%
|
-
|
|
Nov 26
2023
|
Francesca Barone Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,790
+35.34%
|
-
|
|
Nov 26
2023
|
William Garrett Nichols Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,822
+37.62%
|
-
|
|
Nov 26
2023
|
Seshu Tyagarajan Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
104,516
+35.3%
|
-
|
|
Nov 26
2023
|
Paul Peter Tak Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,108
+30.16%
|
-
|
|
Dec 09
2022
|
Joseph C Papa Director |
BUY
Open market or private purchase
|
Direct |
35,018
+47.94%
|
$35,018
$1.94 P/Share
|
|
Dec 09
2022
|
Christopher Martell Director |
BUY
Open market or private purchase
|
Direct |
23,950
+13.61%
|
$23,950
$1.92 P/Share
|
|
Dec 09
2022
|
Seshu Tyagarajan Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
10,358
+43.68%
|
$10,358
$1.93 P/Share
|
|
Dec 09
2022
|
Paul Peter Tak Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,935
+23.99%
|
$12,935
$1.92 P/Share
|
|
Dec 09
2022
|
Jason Amello Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,468
+30.71%
|
$2,468
$1.93 P/Share
|
|
Dec 08
2022
|
Joseph C Papa Director |
BUY
Open market or private purchase
|
Direct |
3,014
+50.0%
|
$3,014
$1.7 P/Share
|
|
Dec 08
2022
|
Christopher Martell Director |
BUY
Open market or private purchase
|
Direct |
3,050
+2.33%
|
$3,050
$1.68 P/Share
|
|
Dec 08
2022
|
Seshu Tyagarajan Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$3,000
$1.69 P/Share
|
|
Dec 08
2022
|
Paul Peter Tak Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,050
+9.81%
|
$3,050
$1.7 P/Share
|
|
Dec 08
2022
|
Francesca Barone Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,238
+31.14%
|
$1,238
$1.61 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 612K shares |
|---|
| Payment of exercise price or tax liability | 113K shares |
|---|